Living With Parkinson's - News in Context and Position Papers - News In Context The Michael J. Fox Foundation - From Teva's ADAGIO Trial: Inconclusive Results, but Possible Disease-modifying Effect, for Azilect (Rasagiline)

Links shared publicly online about this topic.

  • 1,727
    total visits

Living With Parkinson's - News in Context and Position Papers - News In Context The Michael J. Fox Foundation - From Teva's ADAGIO Trial: Inconclusive Results, but Possible Disease-modifying Effect, for Azilect (Rasagiline)

michaeljfox.org —

This week, the New England Journal of Medicine published data from the ADAGIO Phase 3 clinical trial of Israeli drugmaker Teva’s Azilect (rasagiline). The trial was designed to test whether Azilect, which is already approved for symptomatic tre...

View full resource at michaeljfox.org

Tags: Parkinson's Disease, Phase 3 Clinical Trial, Clinical Trial, News

  • Share

Most Recently Shared on September 23, 2009 at 9:09 pm By:

PDOnline PD Online Research

RT: @MJFFNews #PARKINSON'S NEWS: Inconclusive results from ADAGIO trial of rasagiline as disease-modifying treatment http://bit.ly/8OcO4

3 years ago...

Reply

Retweet

Favorite

Also Shared By:

michaeljfox.org michaeljfox.org

Advertisement